aluates Reports

$ 0.0

Automative

Global Personalized Cancer Medicine Market Research Report 2026

Published Date: 2026-01-08

Report Code: QYRE-Auto-11F3068

Global Personalized Cancer Medicine Market Insights Forecast to 2028

BUY CHAPTERS

Global Personalized Cancer Medicine Market Research Report 2026

Code: QYRE-Auto-11F3068

Report

2026-01-08

Pages:133

QYResearch

Buy Now with 15% Discount

DESCRIPTION

TABLE OF CONTENT

TABLES & FIGURES

FEATURED COMPANIES

Merck

Novartis

Amgen Inc

Roche

Astrazeneca plc

Johnson & Johnson

Takeda

AbbVie

Gilead Sciences

Bristol–Myers Squibb

Merck KGaA

Seagen

Eli Lilly

Ono Pharmaceutical

Pfizer Inc

GSK

Exelixis Inc

Regeneron

Innovent

Hengrui Medicine

Johnson & Johnson

Personalized Cancer Medicine Market Size

The global Personalized Cancer Medicine market was valued at US$ 214017 million in 2025 and is anticipated to reach US$ 482388 million by 2032, at a CAGR of 12.5% from 2026 to 2032.

Personalized Cancer Medicine Market

Personalized cancer medicine, also known as targeted therapies or precision medicines, are medications designed to specifically target the unique genetic or molecular characteristics of an individual patient's cancer. These drugs are a central component of personalized cancer medicine and are chosen based on the genomic and molecular profiling of the patient's tumor.

Immunotherapies: While not traditional targeted therapies, immunotherapies like immune checkpoint inhibitors are another form of personalized cancer treatment. These drugs enhance the patient's immune system to recognize and attack cancer cells, and they can be tailored to patients based on their tumor's molecular characteristics.

Personalized cancer treatment drugs have revolutionized cancer care by allowing oncologists to tailor treatment plans to the individual characteristics of each patient's cancer. This approach holds great promise for improving outcomes and reducing the side effects associated with traditional cancer treatments. However, ongoing research and advancements are needed to expand the repertoire of targeted therapies and ensure that they are accessible to more cancer patients.The average gross profit margin of this product is 78%.

Opportunities are driven by the higher response certainty enabled by biomarker-guided therapy and the forward shift of decision-making pathways. As broad molecular profiling and CDx become more embedded in routine practice, treatment selection increasingly moves from organ-based empiricism to molecular stratification, enabling better-matched first-line choices. Tumor-agnostic development further expands markets from “by organ” to “by target/biology,” increasing label-extension potential. Strengthening guideline and real-world consensus on “test first, treat next” supports synchronized growth of testing penetration and prescription accessibility.

Key constraints include evidence thresholds, stratification complexity, and payer sustainability. Biomarkers are not static—tumor heterogeneity, resistance evolution, and testing variability complicate population definition and benefit extrapolation. When access is CDx-dependent, drug and diagnostic registration, supply, and clinical pathways must move in lockstep; otherwise, “drug-ready but test-not-ready” bottlenecks emerge. In parallel, precision regimens often require more sophisticated management (AE handling, combinations, sequencing), raising the bar for standardized quality governance; without clear value evidence and coverage mechanisms, adoption cadence can fluctuate.

Demand is evolving from “finding an actionable target” to “full-cycle precision management.” Broad NGS and CDx are moving earlier in the disease course, refining perioperative and adjuvant decisions. Meanwhile, ctDNA/MRD-driven monitoring is gaining clinical relevance, enabling more real-time relapse-risk assessment, response evaluation, and resistance-mechanism identification—powering closed-loop “test–treat–retest” workflows. Providers increasingly pursue platformized capabilities that integrate molecular pathology, pharmacy governance, imaging, and longitudinal follow-up to build replicable precision-oncology systems and improve multidisciplinary efficiency and patient experience.

Upstream resembles a multi-technology biopharma supply chain. Small-molecule targeted drugs depend on key intermediates, chiral inputs, and high-purity solvent systems, with impurity control and scale-up consistency as the core. Biologics and ADCs rely on cell-line development, media/feed, single-use bioprocess systems, chromatography resins and filtration consumables, plus high-barrier linkers/payloads with stable supply. Cell and gene therapies extend further to plasmids, viral-vector inputs, cell-culture materials, and closed-system manufacturing consumables. As drugs become tightly coupled with diagnostics, upstream quality systems must also align with testing workflows (specimens, reference materials, and QA), making supply continuity and disciplined change control central to regulatory maintenance, commercialization ramp, and global delivery resilience.

This report delivers a comprehensive overview of the global Personalized Cancer Medicine market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Personalized Cancer Medicine. The Personalized Cancer Medicine market size, estimates, and forecasts are provided in terms of revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global Personalized Cancer Medicine market comprehensively. Regional market sizes by Method, by Application, by Route of Administration, and by player are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist Personalized Cancer Medicine manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Method, by Application, and by region.

Market Segmentation

Scope of Personalized Cancer Medicine Market Report

Report Metric	Details
Report Name	Personalized Cancer Medicine Market
Accounted market size in 2025	US$ 214017 million
Forecasted market size in 2032	US$ 482388 million
CAGR	12.5%
Base Year	2025
Forecasted years	2026 - 2032
Segment by Method	Cancer Immunotherapy Targeted Therapy
Segment by Route of Administration	Injection Oral Other
Segment by Therapeutic Modality	Small-molecule Targeted Therapies Antibody Therapies Biomarker-guided Checkpoint Inhibitors Antibody–drug Conjugates Cell & Gene Therapies
Segment by Application	Lung Cancer Breast Cancer Prostate Cancer Blood-related Cancer Other
By Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	AbbVie, Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca, Merck & Co, Takeda, Merck KGaA, Seagen, Eli Lilly, Ono Pharmaceutical, Pfizer, GSK, Exelixis, Regeneron, Innovent, Hengrui Medicine
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Defines the scope of the report and presents an executive summary of market segments (by Method, by Application, by Route of Administration, etc.), including the size of each segment and its future growth potential. It offers a high-level view of the current market and its likely evolution in the short, medium, and long term.
Chapter 2: Summarizes global and regional market size and outlines market dynamics and recent developments, including key drivers, restraints, challenges and risks for industry participants, and relevant policy analysis.
Chapter 3: Provides a detailed view of the competitive landscape for Personalized Cancer Medicine companies, covering revenue share, development plans, and mergers and acquisitions.
Chapter 4: Analyzes segments by Method, detailing the size and growth potential of each segment to help readers identify blue-ocean opportunities.
Chapter 5: Analyzes segments by Application, detailing the size and growth potential of each downstream segment to help readers identify blue-ocean opportunities.
Chapter 6–10: Regional deep dives (North America, Europe, Asia Pacific, Latin America, Middle East & Africa) broken down by country. Each chapter quantifies market size and growth potential by region and key countries, and outlines market development, outlook, addressable space, and capacity.
Chapter 11: Profiles key players, presenting essential information on leading companies, including product/ service offerings, revenue, gross margin, product introductions/portfolios, recent developments, etc.
Chapter 12: Key findings and conclusions of the report.

FAQ for this report

How fast is Personalized Cancer Medicine Market growing?

Ans: The Personalized Cancer Medicine Market witnessing a CAGR of 12.5% during the forecast period 2026-2032.

What is the Personalized Cancer Medicine Market size in 2032?

Ans: The Personalized Cancer Medicine Market size in 2032 will be US$ 482388 million.

Who are the main players in the Personalized Cancer Medicine Market report?

Ans: The main players in the Personalized Cancer Medicine Market are AbbVie, Johnson & Johnson, Novartis, Gilead Sciences, Roche, Bristol-Myers Squibb, Amgen, AstraZeneca, Merck & Co, Takeda, Merck KGaA, Seagen, Eli Lilly, Ono Pharmaceutical, Pfizer, GSK, Exelixis, Regeneron, Innovent, Hengrui Medicine

What are the Application segmentation covered in the Personalized Cancer Medicine Market report?

Ans: The Applications covered in the Personalized Cancer Medicine Market report are Lung Cancer, Breast Cancer, Prostate Cancer, Blood-related Cancer, Other

1 Report Overview

1.1 Study Scope

1.2 Market Analysis by Method

1.2.1 Global Personalized Cancer Medicine Market Size Growth Rate by Method: 2021 vs 2025 vs 2032

1.2.2 Cancer Immunotherapy

1.2.3 Targeted Therapy

1.3 Market by Route of Administration

1.3.1 Global Personalized Cancer Medicine Market Size Growth Rate by Route of Administration: 2021 vs 2025 vs 2032

1.3.2 Injection

1.3.3 Oral

1.3.4 Other

1.4 Market by Therapeutic Modality

1.4.1 Global Personalized Cancer Medicine Market Size Growth Rate by Therapeutic Modality: 2021 vs 2025 vs 2032

1.4.2 Small-molecule Targeted Therapies

1.4.3 Antibody Therapies

1.4.4 Biomarker-guided Checkpoint Inhibitors

1.4.5 Antibody–drug Conjugates

1.4.6 Cell & Gene Therapies

1.5 Market by Application

1.5.1 Global Personalized Cancer Medicine Market Growth by Application: 2021 vs 2025 vs 2032

1.5.2 Lung Cancer

1.5.3 Breast Cancer

1.5.4 Prostate Cancer

1.5.5 Blood-related Cancer

1.5.6 Other

1.6 Assumptions and Limitations

1.7 Study Objectives

1.8 Years Considered

2 Global Growth Trends

2.1 Global Personalized Cancer Medicine Market Perspective (2021–2032)

2.2 Global Personalized Cancer Medicine Growth Trends by Region

2.2.1 Global Personalized Cancer Medicine Market Size by Region: 2021 vs 2025 vs 2032

2.2.2 Personalized Cancer Medicine Historic Market Size by Region (2021–2026)

2.2.3 Personalized Cancer Medicine Forecasted Market Size by Region (2027–2032)

2.3 Personalized Cancer Medicine Market Dynamics

2.3.1 Personalized Cancer Medicine Industry Trends

2.3.2 Personalized Cancer Medicine Market Drivers

2.3.3 Personalized Cancer Medicine Market Challenges

2.3.4 Personalized Cancer Medicine Market Restraints

3 Competition Landscape by Key Players

3.1 Global Top Personalized Cancer Medicine Players by Revenue

3.1.1 Global Top Personalized Cancer Medicine Players by Revenue (2021–2026)

3.1.2 Global Personalized Cancer Medicine Revenue Market Share by Players (2021–2026)

3.2 Global Top Personalized Cancer Medicine Players Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

3.3 Global Key Players Ranking by Personalized Cancer Medicine Revenue

3.4 Global Personalized Cancer Medicine Market Concentration Ratio

3.4.1 Global Personalized Cancer Medicine Market Concentration Ratio (CR5 and HHI)

3.4.2 Global Top 10 and Top 5 Companies by Personalized Cancer Medicine Revenue in 2025

3.5 Global Key Players of Personalized Cancer Medicine Head Offices and Areas Served

3.6 Global Key Players of Personalized Cancer Medicine, Products and Applications

3.7 Global Key Players of Personalized Cancer Medicine, Date of General Availability (GA)

3.8 Mergers and Acquisitions, Expansion Plans

4 Personalized Cancer Medicine Breakdown Data by Method

4.1 Global Personalized Cancer Medicine Historic Market Size by Method (2021–2026)

4.2 Global Personalized Cancer Medicine Forecasted Market Size by Method (2027–2032)

5 Personalized Cancer Medicine Breakdown Data by Application

5.1 Global Personalized Cancer Medicine Historic Market Size by Application (2021–2026)

5.2 Global Personalized Cancer Medicine Forecasted Market Size by Application (2027–2032)

6 North America

6.1 North America Personalized Cancer Medicine Market Size (2021–2032)

6.2 North America Personalized Cancer Medicine Market Growth Rate by Country: 2021 vs 2025 vs 2032

6.3 North America Personalized Cancer Medicine Market Size by Country (2021–2026)

6.4 North America Personalized Cancer Medicine Market Size by Country (2027–2032)

6.5 United States

6.6 Canada

7 Europe

7.1 Europe Personalized Cancer Medicine Market Size (2021–2032)

7.2 Europe Personalized Cancer Medicine Market Growth Rate by Country: 2021 vs 2025 vs 2032

7.3 Europe Personalized Cancer Medicine Market Size by Country (2021–2026)

7.4 Europe Personalized Cancer Medicine Market Size by Country (2027–2032)

7.5 Germany

7.6 France

7.7 U.K.

7.8 Italy

7.9 Russia

7.10 Ireland

8 Asia-Pacific

8.1 Asia-Pacific Personalized Cancer Medicine Market Size (2021–2032)

8.2 Asia-Pacific Personalized Cancer Medicine Market Growth Rate by Region: 2021 vs 2025 vs 2032

8.3 Asia-Pacific Personalized Cancer Medicine Market Size by Region (2021–2026)

8.4 Asia-Pacific Personalized Cancer Medicine Market Size by Region (2027–2032)

8.5 China

8.6 Japan

8.7 South Korea

8.8 Southeast Asia

8.9 India

8.10 Australia & New Zealand

9 Latin America

9.1 Latin America Personalized Cancer Medicine Market Size (2021–2032)

9.2 Latin America Personalized Cancer Medicine Market Growth Rate by Country: 2021 vs 2025 vs 2032

9.3 Latin America Personalized Cancer Medicine Market Size by Country (2021–2026)

9.4 Latin America Personalized Cancer Medicine Market Size by Country (2027–2032)

9.5 Mexico

9.6 Brazil

10 Middle East & Africa

10.1 Middle East & Africa Personalized Cancer Medicine Market Size (2021–2032)

10.2 Middle East & Africa Personalized Cancer Medicine Market Growth Rate by Country: 2021 vs 2025 vs 2032

10.3 Middle East & Africa Personalized Cancer Medicine Market Size by Country (2021–2026)

10.4 Middle East & Africa Personalized Cancer Medicine Market Size by Country (2027–2032)

10.5 Israel

10.6 Saudi Arabia

10.7 UAE

11 Key Players Profiles

11.1 AbbVie

11.1.1 AbbVie Company Details

11.1.2 AbbVie Business Overview

11.1.3 AbbVie Personalized Cancer Medicine Introduction

11.1.4 AbbVie Revenue in Personalized Cancer Medicine Business (2021–2026)

11.1.5 AbbVie Recent Development

11.2 Johnson & Johnson

11.2.1 Johnson & Johnson Company Details

11.2.2 Johnson & Johnson Business Overview

11.2.3 Johnson & Johnson Personalized Cancer Medicine Introduction

11.2.4 Johnson & Johnson Revenue in Personalized Cancer Medicine Business (2021–2026)

11.2.5 Johnson & Johnson Recent Development

11.3 Novartis

11.3.1 Novartis Company Details

11.3.2 Novartis Business Overview

11.3.3 Novartis Personalized Cancer Medicine Introduction

11.3.4 Novartis Revenue in Personalized Cancer Medicine Business (2021–2026)

11.3.5 Novartis Recent Development

11.4 Gilead Sciences

11.4.1 Gilead Sciences Company Details

11.4.2 Gilead Sciences Business Overview

11.4.3 Gilead Sciences Personalized Cancer Medicine Introduction

11.4.4 Gilead Sciences Revenue in Personalized Cancer Medicine Business (2021–2026)

11.4.5 Gilead Sciences Recent Development

11.5 Roche

11.5.1 Roche Company Details

11.5.2 Roche Business Overview

11.5.3 Roche Personalized Cancer Medicine Introduction

11.5.4 Roche Revenue in Personalized Cancer Medicine Business (2021–2026)

11.5.5 Roche Recent Development

11.6 Bristol-Myers Squibb

11.6.1 Bristol-Myers Squibb Company Details

11.6.2 Bristol-Myers Squibb Business Overview

11.6.3 Bristol-Myers Squibb Personalized Cancer Medicine Introduction

11.6.4 Bristol-Myers Squibb Revenue in Personalized Cancer Medicine Business (2021–2026)

11.6.5 Bristol-Myers Squibb Recent Development

11.7 Amgen

11.7.1 Amgen Company Details

11.7.2 Amgen Business Overview

11.7.3 Amgen Personalized Cancer Medicine Introduction

11.7.4 Amgen Revenue in Personalized Cancer Medicine Business (2021–2026)

11.7.5 Amgen Recent Development

11.8 AstraZeneca

11.8.1 AstraZeneca Company Details

11.8.2 AstraZeneca Business Overview

11.8.3 AstraZeneca Personalized Cancer Medicine Introduction

11.8.4 AstraZeneca Revenue in Personalized Cancer Medicine Business (2021–2026)

11.8.5 AstraZeneca Recent Development

11.9 Merck & Co

11.9.1 Merck & Co Company Details

11.9.2 Merck & Co Business Overview

11.9.3 Merck & Co Personalized Cancer Medicine Introduction

11.9.4 Merck & Co Revenue in Personalized Cancer Medicine Business (2021–2026)

11.9.5 Merck & Co Recent Development

11.10 Takeda

11.10.1 Takeda Company Details

11.10.2 Takeda Business Overview

11.10.3 Takeda Personalized Cancer Medicine Introduction

11.10.4 Takeda Revenue in Personalized Cancer Medicine Business (2021–2026)

11.10.5 Takeda Recent Development

11.11 Merck KGaA

11.11.1 Merck KGaA Company Details

11.11.2 Merck KGaA Business Overview

11.11.3 Merck KGaA Personalized Cancer Medicine Introduction

11.11.4 Merck KGaA Revenue in Personalized Cancer Medicine Business (2021–2026)

11.11.5 Merck KGaA Recent Development

11.12 Seagen

11.12.1 Seagen Company Details

11.12.2 Seagen Business Overview

11.12.3 Seagen Personalized Cancer Medicine Introduction

11.12.4 Seagen Revenue in Personalized Cancer Medicine Business (2021–2026)

11.12.5 Seagen Recent Development

11.13 Eli Lilly

11.13.1 Eli Lilly Company Details

11.13.2 Eli Lilly Business Overview

11.13.3 Eli Lilly Personalized Cancer Medicine Introduction

11.13.4 Eli Lilly Revenue in Personalized Cancer Medicine Business (2021–2026)

11.13.5 Eli Lilly Recent Development

11.14 Ono Pharmaceutical

11.14.1 Ono Pharmaceutical Company Details

11.14.2 Ono Pharmaceutical Business Overview

11.14.3 Ono Pharmaceutical Personalized Cancer Medicine Introduction

11.14.4 Ono Pharmaceutical Revenue in Personalized Cancer Medicine Business (2021–2026)

11.14.5 Ono Pharmaceutical Recent Development

11.15 Pfizer

11.15.1 Pfizer Company Details

11.15.2 Pfizer Business Overview

11.15.3 Pfizer Personalized Cancer Medicine Introduction

11.15.4 Pfizer Revenue in Personalized Cancer Medicine Business (2021–2026)

11.15.5 Pfizer Recent Development

11.16 GSK

11.16.1 GSK Company Details

11.16.2 GSK Business Overview

11.16.3 GSK Personalized Cancer Medicine Introduction

11.16.4 GSK Revenue in Personalized Cancer Medicine Business (2021–2026)

11.16.5 GSK Recent Development

11.17 Exelixis

11.17.1 Exelixis Company Details

11.17.2 Exelixis Business Overview

11.17.3 Exelixis Personalized Cancer Medicine Introduction

11.17.4 Exelixis Revenue in Personalized Cancer Medicine Business (2021–2026)

11.17.5 Exelixis Recent Development

11.18 Regeneron

11.18.1 Regeneron Company Details

11.18.2 Regeneron Business Overview

11.18.3 Regeneron Personalized Cancer Medicine Introduction

11.18.4 Regeneron Revenue in Personalized Cancer Medicine Business (2021–2026)

11.18.5 Regeneron Recent Development

11.19 Innovent

11.19.1 Innovent Company Details

11.19.2 Innovent Business Overview

11.19.3 Innovent Personalized Cancer Medicine Introduction

11.19.4 Innovent Revenue in Personalized Cancer Medicine Business (2021–2026)

11.19.5 Innovent Recent Development

11.20 Hengrui Medicine

11.20.1 Hengrui Medicine Company Details

11.20.2 Hengrui Medicine Business Overview

11.20.3 Hengrui Medicine Personalized Cancer Medicine Introduction

11.20.4 Hengrui Medicine Revenue in Personalized Cancer Medicine Business (2021–2026)

11.20.5 Hengrui Medicine Recent Development

12 Analyst's Viewpoints/Conclusions

13 Appendix

13.1 Research Methodology

13.1.1 Methodology/Research Approach

13.1.1.1 Research Programs/Design

13.1.1.2 Market Size Estimation

13.1.1.3 Market Breakdown and Data Triangulation

13.1.2 Data Source

13.1.2.1 Secondary Sources

13.1.2.2 Primary Sources

13.2 Author Details

13.3 Disclaimer

FEATURED COMPANIES

Merck

Novartis

Amgen Inc

Roche

Astrazeneca plc

Johnson & Johnson

Takeda

AbbVie

Gilead Sciences

Bristol–Myers Squibb

Merck KGaA

Seagen

Eli Lilly

Ono Pharmaceutical

Pfizer Inc

GSK

Exelixis Inc

Regeneron

Innovent

Hengrui Medicine

Johnson & Johnson

List of Tables

Table 1. Global Personalized Cancer Medicine Market Size Growth Rate by Method (US$ Million): 2021 vs 2025 vs 2032

Table 2. Key Players of Cancer Immunotherapy

Table 3. Key Players of Targeted Therapy

Table 4. Global Personalized Cancer Medicine Market Size Growth Rate by Route of Administration (US$ Million): 2021 vs 2025 vs 2032

Table 5. Key Players of Injection

Table 6. Key Players of Oral

Table 7. Key Players of Other

Table 8. Global Personalized Cancer Medicine Market Size Growth Rate by Therapeutic Modality (US$ Million): 2021 vs 2025 vs 2032

Table 9. Key Players of Small-molecule Targeted Therapies

Table 10. Key Players of Antibody Therapies

Table 11. Key Players of Biomarker-guided Checkpoint Inhibitors

Table 12. Key Players of Antibody–drug Conjugates

Table 13. Key Players of Cell & Gene Therapies

Table 14. Global Personalized Cancer Medicine Market Size Growth by Application (US$ Million): 2021 vs 2025 vs 2032

Table 15. Global Personalized Cancer Medicine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

Table 16. Global Personalized Cancer Medicine Market Size by Region (US$ Million), 2021–2026

Table 17. Global Personalized Cancer Medicine Market Share by Region (2021–2026)

Table 18. Global Personalized Cancer Medicine Forecasted Market Size by Region (US$ Million), 2027–2032

Table 19. Global Personalized Cancer Medicine Market Share by Region (2027–2032)

Table 20. Personalized Cancer Medicine Market Trends

Table 21. Personalized Cancer Medicine Market Drivers

Table 22. Personalized Cancer Medicine Market Challenges

Table 23. Personalized Cancer Medicine Market Restraints

Table 24. Global Personalized Cancer Medicine Revenue by Players (US$ Million), 2021–2026

Table 25. Global Personalized Cancer Medicine Market Share by Players (2021–2026)

Table 26. Global Top Personalized Cancer Medicine Players by Tier (Tier 1, Tier 2, and Tier 3), based on Personalized Cancer Medicine Revenue, 2025

Table 27. Ranking of Global Top Personalized Cancer Medicine Companies by Revenue (US$ Million) in 2025

Table 28. Global 5 Largest Players Market Share by Personalized Cancer Medicine Revenue (CR5 and HHI), 2021–2026

Table 29. Global Key Players of Personalized Cancer Medicine, Headquarters and Area Served

Table 30. Global Key Players of Personalized Cancer Medicine, Products and Applications

Table 31. Global Key Players of Personalized Cancer Medicine, Date of General Availability (GA)

Table 32. Mergers and Acquisitions, Expansion Plans

Table 33. Global Personalized Cancer Medicine Market Size by Method (US$ Million), 2021–2026

Table 34. Global Personalized Cancer Medicine Revenue Market Share by Method (2021–2026)

Table 35. Global Personalized Cancer Medicine Forecasted Market Size by Method (US$ Million), 2027–2032

Table 36. Global Personalized Cancer Medicine Revenue Market Share by Method (2027–2032)

Table 37. Global Personalized Cancer Medicine Market Size by Application (US$ Million), 2021–2026

Table 38. Global Personalized Cancer Medicine Revenue Market Share by Application (2021–2026)

Table 39. Global Personalized Cancer Medicine Forecasted Market Size by Application (US$ Million), 2027–2032

Table 40. Global Personalized Cancer Medicine Revenue Market Share by Application (2027–2032)

Table 41. North America Personalized Cancer Medicine Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 42. North America Personalized Cancer Medicine Market Size by Country (US$ Million), 2021–2026

Table 43. North America Personalized Cancer Medicine Market Size by Country (US$ Million), 2027–2032

Table 44. Europe Personalized Cancer Medicine Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 45. Europe Personalized Cancer Medicine Market Size by Country (US$ Million), 2021–2026

Table 46. Europe Personalized Cancer Medicine Market Size by Country (US$ Million), 2027–2032

Table 47. Asia-Pacific Personalized Cancer Medicine Market Size Growth Rate by Region (US$ Million): 2021 vs 2025 vs 2032

Table 48. Asia-Pacific Personalized Cancer Medicine Market Size by Region (US$ Million), 2021–2026

Table 49. Asia-Pacific Personalized Cancer Medicine Market Size by Region (US$ Million), 2027–2032

Table 50. Latin America Personalized Cancer Medicine Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 51. Latin America Personalized Cancer Medicine Market Size by Country (US$ Million), 2021–2026

Table 52. Latin America Personalized Cancer Medicine Market Size by Country (US$ Million), 2027–2032

Table 53. Middle East & Africa Personalized Cancer Medicine Market Size Growth Rate by Country (US$ Million): 2021 vs 2025 vs 2032

Table 54. Middle East & Africa Personalized Cancer Medicine Market Size by Country (US$ Million), 2021–2026

Table 55. Middle East & Africa Personalized Cancer Medicine Market Size by Country (US$ Million), 2027–2032

Table 56. AbbVie Company Details

Table 57. AbbVie Business Overview

Table 58. AbbVie Personalized Cancer Medicine Product

Table 59. AbbVie Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026

Table 60. AbbVie Recent Development

Table 61. Johnson & Johnson Company Details

Table 62. Johnson & Johnson Business Overview

Table 63. Johnson & Johnson Personalized Cancer Medicine Product

Table 64. Johnson & Johnson Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026

Table 65. Johnson & Johnson Recent Development

Table 66. Novartis Company Details

Table 67. Novartis Business Overview

Table 68. Novartis Personalized Cancer Medicine Product

Table 69. Novartis Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026

Table 70. Novartis Recent Development

Table 71. Gilead Sciences Company Details

Table 72. Gilead Sciences Business Overview

Table 73. Gilead Sciences Personalized Cancer Medicine Product

Table 74. Gilead Sciences Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026

Table 75. Gilead Sciences Recent Development

Table 76. Roche Company Details

Table 77. Roche Business Overview

Table 78. Roche Personalized Cancer Medicine Product

Table 79. Roche Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026

Table 80. Roche Recent Development

Table 81. Bristol-Myers Squibb Company Details

Table 82. Bristol-Myers Squibb Business Overview

Table 83. Bristol-Myers Squibb Personalized Cancer Medicine Product

Table 84. Bristol-Myers Squibb Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026

Table 85. Bristol-Myers Squibb Recent Development

Table 86. Amgen Company Details

Table 87. Amgen Business Overview

Table 88. Amgen Personalized Cancer Medicine Product

Table 89. Amgen Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026

Table 90. Amgen Recent Development

Table 91. AstraZeneca Company Details

Table 92. AstraZeneca Business Overview

Table 93. AstraZeneca Personalized Cancer Medicine Product

Table 94. AstraZeneca Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026

Table 95. AstraZeneca Recent Development

Table 96. Merck & Co Company Details

Table 97. Merck & Co Business Overview

Table 98. Merck & Co Personalized Cancer Medicine Product

Table 99. Merck & Co Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026

Table 100. Merck & Co Recent Development

Table 101. Takeda Company Details

Table 102. Takeda Business Overview

Table 103. Takeda Personalized Cancer Medicine Product

Table 104. Takeda Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026

Table 105. Takeda Recent Development

Table 106. Merck KGaA Company Details

Table 107. Merck KGaA Business Overview

Table 108. Merck KGaA Personalized Cancer Medicine Product

Table 109. Merck KGaA Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026

Table 110. Merck KGaA Recent Development

Table 111. Seagen Company Details

Table 112. Seagen Business Overview

Table 113. Seagen Personalized Cancer Medicine Product

Table 114. Seagen Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026

Table 115. Seagen Recent Development

Table 116. Eli Lilly Company Details

Table 117. Eli Lilly Business Overview

Table 118. Eli Lilly Personalized Cancer Medicine Product

Table 119. Eli Lilly Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026

Table 120. Eli Lilly Recent Development

Table 121. Ono Pharmaceutical Company Details

Table 122. Ono Pharmaceutical Business Overview

Table 123. Ono Pharmaceutical Personalized Cancer Medicine Product

Table 124. Ono Pharmaceutical Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026

Table 125. Ono Pharmaceutical Recent Development

Table 126. Pfizer Company Details

Table 127. Pfizer Business Overview

Table 128. Pfizer Personalized Cancer Medicine Product

Table 129. Pfizer Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026

Table 130. Pfizer Recent Development

Table 131. GSK Company Details

Table 132. GSK Business Overview

Table 133. GSK Personalized Cancer Medicine Product

Table 134. GSK Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026

Table 135. GSK Recent Development

Table 136. Exelixis Company Details

Table 137. Exelixis Business Overview

Table 138. Exelixis Personalized Cancer Medicine Product

Table 139. Exelixis Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026

Table 140. Exelixis Recent Development

Table 141. Regeneron Company Details

Table 142. Regeneron Business Overview

Table 143. Regeneron Personalized Cancer Medicine Product

Table 144. Regeneron Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026

Table 145. Regeneron Recent Development

Table 146. Innovent Company Details

Table 147. Innovent Business Overview

Table 148. Innovent Personalized Cancer Medicine Product

Table 149. Innovent Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026

Table 150. Innovent Recent Development

Table 151. Hengrui Medicine Company Details

Table 152. Hengrui Medicine Business Overview

Table 153. Hengrui Medicine Personalized Cancer Medicine Product

Table 154. Hengrui Medicine Revenue in Personalized Cancer Medicine Business (US$ Million), 2021–2026

Table 155. Hengrui Medicine Recent Development

Table 156. Research Programs/Design for This Report

Table 157. Key Data Information from Secondary Sources

Table 158. Key Data Information from Primary Sources

Table 159. Authors List of This Report

List of Figures

Figure 1. Personalized Cancer Medicine Picture

Figure 2. Global Personalized Cancer Medicine Market Size Comparison by Method (US$ Million), 2021–2032

Figure 3. Global Personalized Cancer Medicine Market Share by Method: 2025 vs 2032

Figure 4. Cancer Immunotherapy Features

Figure 5. Targeted Therapy Features

Figure 6. Global Personalized Cancer Medicine Market Size Comparison by Route of Administration (US$ Million), 2021–2032

Figure 7. Injection Features

Figure 8. Oral Features

Figure 9. Other Features

Figure 10. Global Personalized Cancer Medicine Market Size Comparison by Therapeutic Modality (US$ Million), 2021–2032

Figure 11. Small-molecule Targeted Therapies Features

Figure 12. Antibody Therapies Features

Figure 13. Biomarker-guided Checkpoint Inhibitors Features

Figure 14. Antibody–drug Conjugates Features

Figure 15. Cell & Gene Therapies Features

Figure 16. Global Personalized Cancer Medicine Market Size by Application (US$ Million), 2021–2032

Figure 17. Global Personalized Cancer Medicine Market Share by Application: 2025 vs 2032

Figure 18. Lung Cancer Case Studies

Figure 19. Breast Cancer Case Studies

Figure 20. Prostate Cancer Case Studies

Figure 21. Blood-related Cancer Case Studies

Figure 22. Other Case Studies

Figure 23. Personalized Cancer Medicine Report Years Considered

Figure 24. Global Personalized Cancer Medicine Market Size (US$ Million), Year-over-Year: 2021–2032

Figure 25. Global Personalized Cancer Medicine Market Size, (US$ Million), 2021 vs 2025 vs 2032

Figure 26. Global Personalized Cancer Medicine Market Share by Region: 2025 vs 2032

Figure 27. Global Personalized Cancer Medicine Market Share by Players in 2025

Figure 28. Global Personalized Cancer Medicine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

Figure 29. The Top 10 and 5 Players Market Share by Personalized Cancer Medicine Revenue in 2025

Figure 30. North America Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 31. North America Personalized Cancer Medicine Market Share by Country (2021–2032)

Figure 32. United States Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 33. Canada Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 34. Europe Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 35. Europe Personalized Cancer Medicine Market Share by Country (2021–2032)

Figure 36. Germany Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 37. France Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 38. U.K. Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 39. Italy Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 40. Russia Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 41. Ireland Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 42. Asia-Pacific Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 43. Asia-Pacific Personalized Cancer Medicine Market Share by Region (2021–2032)

Figure 44. China Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 45. Japan Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 46. South Korea Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 47. Southeast Asia Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 48. India Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 49. Australia & New Zealand Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 50. Latin America Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 51. Latin America Personalized Cancer Medicine Market Share by Country (2021–2032)

Figure 52. Mexico Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 53. Brazil Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 54. Middle East & Africa Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 55. Middle East & Africa Personalized Cancer Medicine Market Share by Country (2021–2032)

Figure 56. Israel Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 57. Saudi Arabia Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 58. UAE Personalized Cancer Medicine Market Size YoY Growth (US$ Million), 2021–2032

Figure 59. AbbVie Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)

Figure 60. Johnson & Johnson Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)

Figure 61. Novartis Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)

Figure 62. Gilead Sciences Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)

Figure 63. Roche Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)

Figure 64. Bristol-Myers Squibb Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)

Figure 65. Amgen Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)

Figure 66. AstraZeneca Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)

Figure 67. Merck & Co Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)

Figure 68. Takeda Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)

Figure 69. Merck KGaA Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)

Figure 70. Seagen Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)

Figure 71. Eli Lilly Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)

Figure 72. Ono Pharmaceutical Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)

Figure 73. Pfizer Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)

Figure 74. GSK Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)

Figure 75. Exelixis Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)

Figure 76. Regeneron Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)

Figure 77. Innovent Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)

Figure 78. Hengrui Medicine Revenue Growth Rate in Personalized Cancer Medicine Business (2021–2026)

Figure 79. Bottom-up and Top-down Approaches for This Report

Figure 80. Data Triangulation

Figure 81. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic

$2900

Single User License

Multi User

Electronic

$4350

Multi User License

Enterprise License

Electronic

$5800

Enterprise License

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Global Cancer Targeted Drug Market Research Report 2025

Global Oncology Targeted Therapy Market Research Report 2025

Global Targeted Radiotherapy Drug Market Research Report 2024

Global Cancer Immuno Personalized Medicine Market Research Report 2024

Global Personalized Medicine for Cancer Market Research Report 2025

Global Precision Cancer Medicine Market Research Report 2024

Global Targeted Oncology Drugs Market Research Report 2024

Global Targeted Cancer Therapy Market Research Report 2024

Global Personalized Precision Medicine Market Research Report 2024

Artificial Intelligence AI in Precision Medicine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Personalized Medicines In Oncology Market Research Report 2024

Global Targeted Small Molecule Drug Market Research Report 2025

Global Cancer Targeted Small Molecule Therapy Market Research Report 2025

Global Targeted Small Molecule Therapy Market Research Report 2025

Global Personalized Cell Therapy Market Research Report 2024

Global Neoantigen Targeted Therapies Market Insights Forecast to 2030

Molecular Targeted Therapy Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030

Global Leukemia Targeted Therapy Drugs Market Research Report 2024

Global Precision Medicine Research and Development Platform Market Research Report 2024

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions